Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Large Growth in Short Interest

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 745 shares, an increase of 102.4% from the December 31st total of 368 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 3,722 shares, the days-to-cover ratio is currently 0.2 days. Based on an average trading volume of 3,722 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the company’s stock are sold short.

Institutional Trading of Ascentage Pharma Group International

Institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in Ascentage Pharma Group International in the third quarter valued at $96,000. ABC Arbitrage SA bought a new stake in Ascentage Pharma Group International in the 3rd quarter valued at about $204,000. Chevy Chase Trust Holdings LLC acquired a new position in Ascentage Pharma Group International during the 2nd quarter worth approximately $227,000. Citadel Advisors LLC bought a new position in Ascentage Pharma Group International in the third quarter worth approximately $383,000. Finally, Hsbc Holdings PLC acquired a new stake in Ascentage Pharma Group International in the second quarter valued at approximately $391,000.

Analysts Set New Price Targets

Several research firms have issued reports on AAPG. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a report on Monday, November 24th. Piper Sandler initiated coverage on Ascentage Pharma Group International in a report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price target for the company. BTIG Research initiated coverage on shares of Ascentage Pharma Group International in a report on Monday, November 10th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, Oppenheimer began coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $48.40.

Ascentage Pharma Group International Price Performance

AAPG stock opened at $24.18 on Friday. The company has a 50 day simple moving average of $28.36 and a 200 day simple moving average of $34.77. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. Ascentage Pharma Group International has a 1 year low of $17.09 and a 1 year high of $48.45.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.